The effect of GAD-alum on preserving endogenous insulin production has been evaluated in several placebo-controlled, randomised trials in individuals recently diagnosed with type 1 diabetes, albeit with inconclusive results [1–4]. The gene discussed is INS; the disease is type 1 diabetes mellitus.